Give the high rate of advances in the field of clinical hematology, the IACH News initiative enables experts in the field and key opinion leaders share the most up to date information in a timely manner, and in a format that is, focused, engaging and easy to access.

November 5th- Beyond the Webinar: How should we manage chemotherapy-induced thrombocytopenia, or CIT, and what is the role of thrombopoietin-receptor agonists?

CME Congresses .

November 5th- Beyond the Webinar: How should we manage chemotherapy-induced thrombocytopenia, or CIT, and what is the role of thrombopoietin-receptor agonists?

November 2nd- Thrombopénie et chimiothérapie: comment éviter les interruptions de traitement ?

CME Congresses .

November 2nd- Thrombopénie et chimiothérapie: comment éviter les interruptions de traitement ?

November 2nd- Why is cilta-cel so effective? The CAR promoter may be part of the answer

CME Congresses .

November 2nd- Why is cilta-cel so effective? The CAR promoter may be part of the answer

October 30th- Beyond the Webinar: Chronic GVHD: Moving Beyond Steroids Towards Precision and Personalized Treatment

CME Congresses .

October 30th- Beyond the Webinar: Chronic GVHD: Moving Beyond Steroids Towards Precision and Personalized Treatment

October 28th- Beyond the Webinar: Anti-CD38 mAb-based strategies across the myeloma continuum

CME Congresses .

October 28th- Beyond the Webinar: Anti-CD38 mAb-based strategies across the myeloma continuum

October 26th- From IMiDs to CELMoDs: 30 Years of Cereblon Biology in Multiple Myeloma

CME Congresses .

October 26th- From IMiDs to CELMoDs: 30 Years of Cereblon Biology in Multiple Myeloma

October 22nd- Beyond the Webinar: CELMoDs in Multiple Myeloma: A New Era of Cereblon Modulation

CME Congresses .

October 22nd- Beyond the Webinar: CELMoDs in Multiple Myeloma: A New Era of Cereblon Modulation

October 19th- Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma

CME Congresses .

October 19th- Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma

October 13th- Beyond the Webinar: The 23rd International Myeloma Society Congress in Glasgow

CME Congresses .

October 13th- Beyond the Webinar: The 23rd International Myeloma Society Congress in Glasgow

October 19th- Teclistamab in high-risk smoldering multiple myeloma

CME Congresses .

October 19th- Teclistamab in high-risk smoldering multiple myeloma

IACH News Podcasts

November 5th- Beyond the Webinar: ​How should we manage chemotherapy-induced thrombocytopenia, or CIT, and what is the role of thrombopoietin-receptor agonists?

November 2nd- Thrombopénie et chimiothérapie: comment éviter les interruptions de traitement ?

November 2nd- Why is cilta-cel so effective? The CAR promoter may be part of the answer

October 30th- Beyond the Webinar: Chronic GVHD: Moving Beyond Steroids Towards Precision and Personalized Treatment

October 28th- Beyond the Webinar: Anti-CD38 mAb-based strategies across the myeloma continuum

October 26th- From IMiDs to CELMoDs: 30 Years of Cereblon Biology in Multiple Myeloma

October 22nd- Beyond the Webinar: CELMoDs in Multiple Myeloma: A New Era of Cereblon Modulation

October 19th- Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma

October 13th- Beyond the Webinar: The 23rd International Myeloma Society Congress in Glasgow

October 19th- Teclistamab in high-risk smoldering multiple myeloma

November 5th- Beyond the Webinar: How should we manage chemotherapy-induced thrombocytopenia, or CIT, and what is the role of thrombopoietin-receptor agonists?